22 results
8-K
EX-99.1
CGTX
Cognition Therapeutics Inc
26 Mar 24
Cognition Therapeutics Reports Year End 2023 Financial Results and Provides Business Update
7:12am
-to-moderate dementia with Lewy bodies (DLB); topline results expected in 2H2024
Initiated site activation and recruitment in Phase 2 START Study in early
424B5
CGTX
Cognition Therapeutics Inc
13 Mar 24
Prospectus supplement for primary offering
4:04pm
(COG0203) study of CT1812 in patients with early-stage AD. We received clearance from the FDA to proceed with the START clinical trial and recruitment has
424B5
CGTX
Cognition Therapeutics Inc
11 Mar 24
Prospectus supplement for primary offering
4:06pm
-stage AD. We received clearance from the FDA to proceed with the START clinical trial and recruitment has commenced. We intend to enroll 540 adults
8-K
EX-99.1
lof1eolbhc
4 Jan 24
Other Events
4:21pm
8-K
EX-99.1
drmfdg kihr743w6y
2 Nov 23
Cognition Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
7:41am
8-K
EX-99.1
le216hlba34 cz1y
8 Aug 23
Cognition Therapeutics Reports Second Quarter 2023 Financial Results and Business Update
7:05am
DEF 14A
naznd3q
25 Apr 22
Definitive proxy
5:28pm
S-1
EX-10.27
id50jq
19 Jul 21
IPO registration
7:02am
S-1
EX-10.31
nv3oi0r5 6f574
19 Jul 21
IPO registration
7:02am
S-1
EX-10.24
bhf6b mj63j0yjz
19 Jul 21
IPO registration
7:02am
S-1
EX-10.25
9s3qvhsac ant64q
19 Jul 21
IPO registration
7:02am
S-1
EX-10.32
vyh8z70
19 Jul 21
IPO registration
7:02am
S-1
EX-10.33
yn38 cbqmj
19 Jul 21
IPO registration
7:02am
DRS/A
EX-10.24
za29wfbym4ll8i
23 Jun 21
Draft registration statement (amended)
12:00am
DRS/A
EX-10.22
hlxj1ni 2m67n
23 Jun 21
Draft registration statement (amended)
12:00am
DRS/A
EX-10.30
i3gzwwkfnfkvfld6 is
23 Jun 21
Draft registration statement (amended)
12:00am
DRS/A
EX-10.28
zh4zhj
23 Jun 21
Draft registration statement (amended)
12:00am